Lexicon Q2 net loss $31.8M; SONATA-HCM enrollment complete; ZYNQUISTA NDA resubmission Q4 2026

LEXICON PHARMACEUTICALS, INC.

Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025; total revenue $0.7M (all INPEFA) vs $28.9M (incl $27.6M licensing) YoY.
Cash and investments $190.6M at June 30, 2026, up from $125.2M at Dec 31, 2025; $100M Hercules loan facility entered, $55M drawn.
SONATA-HCM Phase 3 enrollment completed (exceeded 500 patients); top-line data expected Q1 2027.
ZYNQUISTA NDA resubmission for T1D expected Q4 2026, pending STENO1 safety data.
LX9851 Phase 1 by Novo Nordisk ongoing; Lexicon eligible for up to $1B milestones plus royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.